Multiple Dose Pharmacokinetics of Intranasal Ketamine

Phase 1CompletedNCT00519987

Javelin Pharmaceuticals18 enrolled

Overview

This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.

To examine safety and characterize the repeat dosing plasma profile, effect on absorption, and accumulation following repeated administration of 30 mg doses of PMI-150 (intranasal ketamine) to healthy adult volunteers.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

intranasal ketamineDRUG

intranasal ketamine

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy adults Exclusion Criteria: * under 18 years

Outcomes

Primary Outcomes

pharmacokinetics

Time frame: multiple

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.